NCT03583021

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male

Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Ajou University School of Medicine · Academic / Other
• Sex: Male
• Age: 65 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in male patients who are reversed with sugammadex or neostigmine.

Detailed description

Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time during extubation. In addition, cough suppression of remifentanil enables smooth extubation with reduced complications. However, the infusion of remifentanil suppresses the emergence cough effectively in clinical practice, whereas it still delays the awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil during emergence would decrease the adverse events that are associated with remifentanil infusion.

Conditions

• Gallbladder Diseases

Interventions

Type	Name	Description
DRUG	Sugammadex Injectable Product	Sugammadex of 3 mg/kg is injected.
DRUG	Neostigmine Injectable Product	Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.

Timeline

• Start date: 2018-06-25
• Primary completion: 2018-10-31
• Completion: 2018-12-31
• First posted: 2018-07-11
• Last updated: 2020-05-29

Locations

1 site across 1 country: South Korea